Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.61%
#2 Luxxcoin Luxxcoin +45.15%
#3 ResearchCoin ResearchCoin +21.62%
#4 Reactive Network Reactive Network +21.45%
#5 Layer3 Layer3 +19.67%
#6 Orderly Network Orderly Network +16.55%
#7 Aria.AI Aria.AI +12.61%
#8 Bitgert Bitgert +11.76%
#9 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.32%
#10 KAITO KAITO +9.04%
Coin of the day
Resolv wstUSR Resolv wstUSR
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
CSL Limited CSL Limited

CSL Limited

CSL
Rang in Aktien #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Aktienkurs
$99.32
Marktkapitalisierung
$48.20B
Veränderung (1 Tag)
0.98%
Veränderung (1 Jahr)
-32.14%
Land
AU
Handel CSL Limited (CSL)

Kategorie

Healthcare
Gewinn für CSL Limited (CSL)
Gewinn im Dec 2025 TTM: $1.61B
Laut den aktuellen Finanzberichten von CSL Limited betragen die aktuellen Gewinne des Unternehmens $1.61B. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $3.38B, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $2.66B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von CSL Limited von 2000 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $1.61B -56.65%
2025 $3.72B 10.34%
2024 $3.38B 26.74%
2023 $2.66B -4.19%
2022 $2.78B -6.80%
2021 $2.98B 15.92%
2020 $2.57B 9.89%
2019 $2.34B 2.63%
2018 $2.28B 35.00%
2017 $1.69B 8.61%
2016 $1.56B -9.22%
2015 $1.71B 6.84%
2014 $1.60B 19.64%
2013 $1.34B 5.36%
2012 $1.27B -7.31%
2011 $1.37B 38.29%
2010 $992.87M 11.00%
2009 $894.45M 2.37%
2008 $873.74M 56.73%
2007 $557.47M 493.43%
2006 $93.94M -74.77%
2005 $372.39M 201.20%
2004 $123.64M 168.99%
2003 $45.96M -7.38%
2002 $49.63M -8.38%
2001 $54.17M 88.04%
2000 $28.81M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.51B 1,170.24%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B 187.63%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 224.03%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B 32.42%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -10.11%
NL